Research programme: Neurological disorders therapeutics - Asceneuron
Latest Information Update: 03 Nov 2016
At a glance
- Originator Merck Serono
- Developer Asceneuron
- Class Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors; Hexosaminidase C inhibitors; Tau protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Progressive supranuclear palsy